Paul Thomen

Saturday, 18 January 2014

Atopic Dermatitis Market for France and Germany Drug Forecast

The report “PharmaPoint: Atopic Dermatitis – France and Germany Drug Forecast and Market Analysis to 2022″ by GlobalData is now available at Contact with PharmaPoint: Atopic Dermatitis – France and Germany Drug Forecast and Market Analysis to 2022 in subject line and your contact details to purchase this report or get your questions answered.

The collection of ‘Dermatology therapeutics’ market research reports has a new addition of “PharmaPoint: Atopic Dermatitis – France and Germany Drug Forecast and Market Analysis to 2022” on 

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly generalized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.
Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.


  • Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in France and Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in France and Germany from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting France and Germany Atopic Dermatitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in France and Germany

List of Tables

Table 1: Symptoms of Atopic Dermatitis 19
Table 2: Treatment Guidelines for Atopic Dermatitis 25
Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013 27
Table 4: Referral Rates to a French
and German Dermatologist, Split by Severity and Specialist Type, 2013 29
Table 5: Key Metrics Relating to the Diagnosis, Relapse and Remission Rates of Atopic Dermatitis in France
and Germany in 2012 29
Table 6: Leading Treatments for Atopic Dermatitis, 2013 34
Table 7: Product Profile - Protopic 36
Table 8: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients 37
Table 9: Protopic SWOT Analysis, 2013 40
Table 10: Product Profile - Elidel 42
Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies 43
Table 12: Elidel SWOT Analysis, 2013 45
Table 13: Product Profile - Cyclosporine 47
Table 14: Cyclosporine SWOT Analysis, 2013 49
Table 15: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2013 50
Table 16: Product Profile - Xolair 52
Table 17: Xolair SWOT Analysis, 2013 54
Table 18: Product Profile - Actimmune 56
Table 19: Actimmune SWOT Analysis, 2013 58
Table 20: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment 60
Table 21: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013 67
Table 22: Late-Stage Atopic Dermatitis Pipeline, 2013 72
Table 23: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013 73
Table 24: Product Profile - Dupilumab 75
Table 25: Ongoing Clinical Trials of Dupilumab in Atopic Dermatitis Patients, as of September 2013 77
Table 26: Dupilumab SWOT Analysis, 2013 82
Table 27: Phase II and Phase I Atopic Dermatitis Pipeline, 2013 83
Table 28: Global Atopic Dermatitis Market - Drivers and Barriers, 2012-2022 84
Table 29: Sales Forecasts ($m) for Atopic Dermatitis in France and Germany, 2012-2022 91
Table 30: Key Event Impacting Sales for Atopic Dermatitis in France
and Germany, 2012-2022 92
Table 31: Atopic Dermatitis Market in France
and Germany - Drivers and Barriers, 2012-2022 93
Table 32: Key Launch Dates 107
Table 33: Key Patent Expiries 107
Table 34: Physicians Surveyed, By Country 112

For further information on PharmaPoint: Atopic Dermatitis – France and Germany Drug Forecast and Market Analysis to 2022” report OR for any other business research / market intelligence need on the ‘Dermatology therapeutics’ market ( .), contact / Call +1 888 391 5441.

About Us: is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers. RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:
Corporate Office:
TX, Dallas North - Dominion Plaza,
17304, Preston Road, Suite 800,
 Dallas 75252.
Tel: + 1 888 391 5441

For More Information Kindly Contact:

No comments:

Post a Comment

Note: only a member of this blog may post a comment.